MA39881B1 - Dérivés de cholane à utiliser dans le traitement et/ou la prévention de maladies médiées par fxr et tgr5/gpbar1 - Google Patents
Dérivés de cholane à utiliser dans le traitement et/ou la prévention de maladies médiées par fxr et tgr5/gpbar1Info
- Publication number
- MA39881B1 MA39881B1 MA39881A MA39881A MA39881B1 MA 39881 B1 MA39881 B1 MA 39881B1 MA 39881 A MA39881 A MA 39881A MA 39881 A MA39881 A MA 39881A MA 39881 B1 MA39881 B1 MA 39881B1
- Authority
- MA
- Morocco
- Prior art keywords
- gpbar1
- tgr5
- fxr
- prevention
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
La présente invention concerne des composés possédant des squelettes cholane de formule (i), lesdits composés étant destinés à être utilisés dans le traitement et/ou la prévention de maladies médiées par fxr et tgr5/gpbar1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITFI20140130 | 2014-05-29 | ||
EP15731260.4A EP3149019B1 (fr) | 2014-05-29 | 2015-05-28 | Dérivés de cholane à utiliser dans le traitement et/ou la prévention de maladies médiées par fxr et tgr5/gpbar1 |
PCT/EP2015/061802 WO2015181275A1 (fr) | 2014-05-29 | 2015-05-28 | Dérivés de cholane à utiliser dans le traitement et/ou la prévention de maladies médiées par fxr et tgr5/gpbar1 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA39881B1 true MA39881B1 (fr) | 2020-02-28 |
Family
ID=51454763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39881A MA39881B1 (fr) | 2014-05-29 | 2015-05-28 | Dérivés de cholane à utiliser dans le traitement et/ou la prévention de maladies médiées par fxr et tgr5/gpbar1 |
Country Status (24)
Country | Link |
---|---|
US (2) | US10407462B2 (fr) |
EP (2) | EP3149019B1 (fr) |
JP (1) | JP6820253B2 (fr) |
KR (1) | KR102491556B1 (fr) |
CN (2) | CN106661079B (fr) |
AU (1) | AU2015265893B2 (fr) |
CA (1) | CA2948585C (fr) |
CY (1) | CY1122631T1 (fr) |
DK (2) | DK3626725T3 (fr) |
EA (1) | EA032820B1 (fr) |
ES (2) | ES2768718T3 (fr) |
FI (1) | FI3626725T3 (fr) |
HR (2) | HRP20230170T1 (fr) |
HU (2) | HUE048351T2 (fr) |
LT (2) | LT3149019T (fr) |
MA (1) | MA39881B1 (fr) |
MX (2) | MX2016015724A (fr) |
PH (1) | PH12016502327A1 (fr) |
PL (2) | PL3626725T3 (fr) |
PT (2) | PT3626725T (fr) |
RS (2) | RS59910B1 (fr) |
SG (2) | SG10201809362RA (fr) |
SI (2) | SI3149019T1 (fr) |
WO (1) | WO2015181275A1 (fr) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2545964A1 (fr) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité |
DK3626725T3 (da) * | 2014-05-29 | 2023-02-27 | Bar Pharmaceuticals S R L | Cholan-derivater til anvendelse ved behandlingen og/eller forebyggelsen af fxr- og tgr5/gpbar1-medierede sygdomme |
WO2016045480A1 (fr) * | 2014-09-28 | 2016-03-31 | 上海源力生物技术有限公司 | Procédé de préparation d'acide obéticholique |
WO2016073767A1 (fr) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Analogues d'acide biliaire d'agonistes de fxr/tgr5 et leurs procédés d'utilisation |
CN111944006B (zh) * | 2014-11-17 | 2021-12-17 | 正大天晴药业集团股份有限公司 | 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途 |
TWI688571B (zh) | 2014-11-19 | 2020-03-21 | 英商Nzp英國有限公司 | 化合物(四) |
WO2016079518A1 (fr) | 2014-11-19 | 2016-05-26 | Dextra Laboratories Limited | Stéroïdes 5.bêta.-6-alkyl-7-hydroxy-3-one utilisés en tant qu'intermédiaires pour la production de modulateurs de fxr stéroïdiens |
DK3221331T3 (da) | 2014-11-19 | 2019-12-02 | Nzp Uk Ltd | 6-alkyl-7-hydroxy-4-en-3-on-steroider som mellemprodukter til fremstilling af steroide fxr-modulatorer |
CA2968305A1 (fr) | 2014-11-19 | 2016-05-26 | NZP UK Limited | Steroides 6.alpha.-alkyl-3,7-dione utilises en tant qu'intermediaires pour la production de modulateurs de fxr steroidiens |
CN107231795A (zh) | 2014-11-26 | 2017-10-03 | 英安塔制药有限公司 | 作为fxr/tgr5激动剂的胆汁酸类似物及其使用方法 |
US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
WO2016086115A1 (fr) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Dérivés de tétrazole d'acides biliaires utilisés en tant qu'agonistes de fxr/tgr5 et leurs procédés d'utilisation |
US10246483B2 (en) | 2015-02-11 | 2019-04-02 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
NZ735126A (en) | 2015-03-31 | 2022-10-28 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
DK3310801T3 (da) | 2015-06-19 | 2021-06-21 | Intercept Pharmaceuticals Inc | Tgr5-modulatorer og fremgangsmåder til anvendelse deraf |
WO2017053826A1 (fr) | 2015-09-24 | 2017-03-30 | Intercept Pharmaceuticals, Inc. | Procédés et intermédiaires pour la préparation de dérivés de l'acide biliaire |
WO2017147174A1 (fr) * | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Analogues de l'acide biliaire contenant de l'hétéroaryle utilisés comme agonistes de fxr/tgr5 et leurs méthodes d'utilisation |
WO2017147137A1 (fr) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Dérivés d'acide benzoïque d'acide biliaire utilisés en tant qu'agonistes de fxr/tgr5 et leurs méthodes d'utilisation |
US10364267B2 (en) | 2016-02-23 | 2019-07-30 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
ES2874682T3 (es) | 2016-03-11 | 2021-11-05 | Intercept Pharmaceuticals Inc | Derivados de 3-desoxi y composiciones farmacéuticas de los mismos |
CN105859817A (zh) * | 2016-05-09 | 2016-08-17 | 成都宇西医药技术有限公司 | 一种制备3α-羟基-6-乙烯基-7-酮基-5β-胆烷酸的方法 |
GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
WO2017207648A1 (fr) | 2016-05-31 | 2017-12-07 | Bionice, S.L.U | Procédés et intermédiaires pour la préparation d'acide obéticholique et de dérivés de celui-ci |
WO2017208165A1 (fr) * | 2016-06-01 | 2017-12-07 | Dr. Reddy’S Laboratories Limited | Procédé de préparation d'acide obéticholique |
EP3730487B1 (fr) | 2016-06-13 | 2022-04-27 | Gilead Sciences, Inc. | Dérivés d'azetidine en tant que modulateurs de fxr (nr1h4) |
CA2968836A1 (fr) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Composes modulant fxr (nr1h4) |
IT201600068742A1 (it) * | 2016-07-01 | 2018-01-01 | Bar Pharmaceuticals Soc A Responsabilita Limitata | Derivati dell'acido iodesossicolico e loro uso |
AU2017368069B2 (en) | 2016-11-29 | 2021-07-08 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
US10472386B2 (en) | 2017-02-14 | 2019-11-12 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR agonists and methods of use thereof |
KR20190126920A (ko) | 2017-03-28 | 2019-11-12 | 길리애드 사이언시즈, 인코포레이티드 | 간 질환을 치료하기 위한 치료 조합물 |
CA3058754A1 (fr) | 2017-04-07 | 2018-10-11 | Enanta Pharmaceuticals, Inc. | Procede de preparation de derives sulfonylcarbamate d'acides biliaires |
CN109021054B (zh) * | 2017-06-09 | 2021-04-09 | 博瑞生物医药(苏州)股份有限公司 | 一种fxr激动剂 |
CN109021055B (zh) * | 2017-06-09 | 2021-04-09 | 博瑞生物医药(苏州)股份有限公司 | Fxr激动剂 |
CN109021056B (zh) * | 2017-06-09 | 2021-03-09 | 博瑞生物医药(苏州)股份有限公司 | 法尼酯x受体激动剂 |
CN110869381B (zh) * | 2017-07-26 | 2021-11-19 | 正大天晴药业集团股份有限公司 | 甾体类衍生物fxr激动剂的制备方法 |
EP3705487B1 (fr) * | 2017-11-02 | 2022-10-26 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Procédé de préparation de composé d'acide cholique |
EA202191566A1 (ru) | 2019-01-15 | 2021-11-01 | Джилид Сайенсиз, Инк. | Соединения, модулирующие fxr (nr1h4) |
CA3129949C (fr) | 2019-02-19 | 2024-04-30 | Gilead Sciences, Inc. | Formes solides d'agonistes de fxr |
EP4041722A4 (fr) | 2019-10-07 | 2023-12-13 | Kallyope, Inc. | Agonistes de gpr119 |
CN112824425B (zh) * | 2019-11-21 | 2023-10-03 | 成都西岭源药业有限公司 | 一种6-位烯基取代胆酸化合物及其制备方法和应用 |
IT202000008515A1 (it) | 2020-04-21 | 2021-10-21 | Bar Pharmaceuticals Soc A Responsabilita Limitata | Metodo per la sintesi di un derivato del colano |
KR20230012597A (ko) | 2020-05-19 | 2023-01-26 | 칼리오페, 인크. | Ampk 활성화제 |
JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ,インク. | Ampkアクチベーター |
WO2023233346A1 (fr) * | 2022-06-01 | 2023-12-07 | Precision Bio-Therapeutics S.R.L. | Dérivés de cholestérol et leurs utilisations |
WO2024006537A1 (fr) * | 2022-07-01 | 2024-01-04 | Intercept Pharmaceuticals, Inc. | Procédés pour améliorer une déficience cognitive à l'aide de dérivés d'acide biliaire |
WO2024097247A1 (fr) * | 2022-10-31 | 2024-05-10 | Intercept Pharmaceuticals, Inc. | Utilisations d'agonistes du récepteur farnésoïde x |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2326850T3 (es) * | 1998-12-23 | 2009-10-20 | Glaxo Group Limited | Ensayos para ligandos de receptores nucleares. |
ATE303399T1 (de) * | 2001-03-12 | 2005-09-15 | Intercept Pharmaceuticals Inc | Steroide als agonisten für fxr |
EP1568706A1 (fr) * | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Nouveau agonist steroidal pour FXR |
PL1734970T3 (pl) * | 2004-03-12 | 2015-05-29 | Intercept Pharmaceuticals Inc | Leczenie zwłóknienia z zastosowaniem ligandów FXR |
ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
AU2007265457C1 (en) | 2006-06-27 | 2012-11-29 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions |
US8940719B2 (en) * | 2006-07-03 | 2015-01-27 | Academia Sinica | Lithocholic acid analogues that inhibit sialyltransferase |
FR2908310B1 (fr) * | 2006-11-14 | 2009-07-10 | Phytodia | Produits agonistes de tgr5 et leurs applications |
EP1947108A1 (fr) * | 2007-01-19 | 2008-07-23 | Intercept Pharmaceuticals, Inc. | Modulateurs TGR5 et procédés d'utilisation correspondants |
ES2438271T3 (es) * | 2007-01-19 | 2014-01-16 | Intercept Pharmaceuticals, Inc. | Ácidos biliares 23-sustituidos como moduladores de TGR5 y métodos de uso de los mismos |
CN105037476B (zh) | 2008-07-30 | 2018-06-12 | 英特塞普特医药品公司 | Tgr5调节剂及其使用方法 |
CN106380502A (zh) * | 2008-11-19 | 2017-02-08 | 英特塞普特医药品公司 | G蛋白偶联受体5(tgr5)调节剂及其使用方法 |
DK2698375T3 (en) * | 2008-11-19 | 2018-05-28 | Intercept Pharmaceuticals Inc | TGR5 modulators and methods for using them |
ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
US20130261317A1 (en) * | 2010-09-27 | 2013-10-03 | Kythera Biopharmaceuticals, Inc. | Methods for preparing synthetic bile acids and compositions comprising the same |
EP2739286A4 (fr) | 2011-08-04 | 2015-06-03 | Lumena Pharmaceuticals Inc | Inhibiteurs du recyclage de l'acide biliaire dans le traitement du pancréas |
SG10201607230SA (en) * | 2012-06-19 | 2016-10-28 | Intercept Pharmaceuticals Inc | Preparation, Uses And Solid Forms Of Obeticholic Acid |
KR102068381B1 (ko) * | 2012-10-26 | 2020-01-20 | 인터셉트 파마슈티컬즈, 인크. | 담즙산 유도체의 제조 방법 |
US20140206657A1 (en) * | 2013-01-18 | 2014-07-24 | City Of Hope | Bile acid analog tgr5 agonists |
CN103143021A (zh) * | 2013-03-21 | 2013-06-12 | 中国药科大学 | PPARα-UGT通路抑制剂在治疗炎性肠疾病中的应用 |
MY187886A (en) * | 2013-05-14 | 2021-10-26 | Intercept Pharmaceuticals Inc | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
CN105593237B (zh) * | 2013-08-01 | 2019-06-04 | 美国卫生和人力服务部 | 法尼醇x受体的抑制剂和在医学中的用途 |
US10166246B2 (en) * | 2014-05-27 | 2019-01-01 | City Of Hope | TGR5 agonist complexes for treating diabetes and cancer |
DK3626725T3 (da) | 2014-05-29 | 2023-02-27 | Bar Pharmaceuticals S R L | Cholan-derivater til anvendelse ved behandlingen og/eller forebyggelsen af fxr- og tgr5/gpbar1-medierede sygdomme |
US20170233431A1 (en) * | 2016-02-17 | 2017-08-17 | City Of Hope | Bile acid derivatives and methods for synthesis and use |
-
2015
- 2015-05-28 DK DK19204247.1T patent/DK3626725T3/da active
- 2015-05-28 RS RS20200163A patent/RS59910B1/sr unknown
- 2015-05-28 CN CN201580028528.2A patent/CN106661079B/zh active Active
- 2015-05-28 SI SI201531091T patent/SI3149019T1/sl unknown
- 2015-05-28 MX MX2016015724A patent/MX2016015724A/es active IP Right Grant
- 2015-05-28 MX MX2020004024A patent/MX2020004024A/es unknown
- 2015-05-28 PL PL19204247.1T patent/PL3626725T3/pl unknown
- 2015-05-28 KR KR1020167034084A patent/KR102491556B1/ko active IP Right Grant
- 2015-05-28 HR HRP20230170TT patent/HRP20230170T1/hr unknown
- 2015-05-28 SG SG10201809362RA patent/SG10201809362RA/en unknown
- 2015-05-28 SI SI201531924T patent/SI3626725T1/sl unknown
- 2015-05-28 PT PT192042471T patent/PT3626725T/pt unknown
- 2015-05-28 JP JP2017514960A patent/JP6820253B2/ja active Active
- 2015-05-28 PT PT157312604T patent/PT3149019T/pt unknown
- 2015-05-28 US US15/314,771 patent/US10407462B2/en active Active
- 2015-05-28 SG SG11201609403UA patent/SG11201609403UA/en unknown
- 2015-05-28 LT LTEP15731260.4T patent/LT3149019T/lt unknown
- 2015-05-28 ES ES15731260T patent/ES2768718T3/es active Active
- 2015-05-28 EP EP15731260.4A patent/EP3149019B1/fr active Active
- 2015-05-28 HU HUE15731260A patent/HUE048351T2/hu unknown
- 2015-05-28 WO PCT/EP2015/061802 patent/WO2015181275A1/fr active Application Filing
- 2015-05-28 MA MA39881A patent/MA39881B1/fr unknown
- 2015-05-28 LT LTEP19204247.1T patent/LT3626725T/lt unknown
- 2015-05-28 EP EP19204247.1A patent/EP3626725B1/fr active Active
- 2015-05-28 CA CA2948585A patent/CA2948585C/fr active Active
- 2015-05-28 AU AU2015265893A patent/AU2015265893B2/en active Active
- 2015-05-28 PL PL15731260T patent/PL3149019T3/pl unknown
- 2015-05-28 ES ES19204247T patent/ES2938874T3/es active Active
- 2015-05-28 DK DK15731260.4T patent/DK3149019T3/da active
- 2015-05-28 RS RS20230132A patent/RS64050B1/sr unknown
- 2015-05-28 EA EA201692316A patent/EA032820B1/ru unknown
- 2015-05-28 CN CN201910107511.6A patent/CN110003301B/zh active Active
- 2015-05-28 FI FIEP19204247.1T patent/FI3626725T3/fi active
- 2015-05-28 HU HUE19204247A patent/HUE061506T2/hu unknown
-
2016
- 2016-11-22 PH PH12016502327A patent/PH12016502327A1/en unknown
-
2019
- 2019-08-01 US US16/529,571 patent/US11117926B2/en active Active
-
2020
- 2020-02-11 HR HRP20200225TT patent/HRP20200225T1/hr unknown
- 2020-02-12 CY CY20201100131T patent/CY1122631T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39881B1 (fr) | Dérivés de cholane à utiliser dans le traitement et/ou la prévention de maladies médiées par fxr et tgr5/gpbar1 | |
PH12017500941A1 (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
MY192717A (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
MX2019003790A (es) | Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos. | |
EA201790998A1 (ru) | Иммуннорегуляторные агенты | |
EA201790992A1 (ru) | Иммунорегуляторные агенты | |
MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
EA201790271A1 (ru) | Ингибиторы гликозидазы | |
MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
MA39172B1 (fr) | Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines | |
MA38483A1 (fr) | Inhibiteurs de l'ido | |
EA201990044A1 (ru) | Гетероциклические соединения в качестве антибактериальных средств | |
EA201890256A1 (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
MA41238B1 (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
MA47356B1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
MA34968B1 (fr) | Urées asymétriques et utilisations médicales de celles-ci | |
MA40302B1 (fr) | Dérivés de carbazole | |
MA40875B1 (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
MA40221A (fr) | Dérivés d'isoindoline à utiliser dans le traitement d'une infection virale | |
TW201613896A (en) | Novel 2,5-substituted pyrimidines | |
EA202190272A1 (ru) | Дополнительно замещенные производные триазолохиноксалина | |
MA44020B1 (fr) | Composés antitumoraux | |
MA39171A1 (fr) | Dérivés d'hydroxy formamide et leur utilisation | |
MA39315A1 (fr) | Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique | |
EA202190271A1 (ru) | Замещенные триазолохиноксалиновые производные |